


## AAPK-25

## Chemical Properties

|                   |   |
|-------------------|---|
| CAS No. :         | 2247919-28-2  |
| Formula:          | C <sub>21</sub> H <sub>13</sub> Cl <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S                                     |
| Molecular Weight: | 442.32  |
| Storage:          | Powder: -20°C for 3 years   In solvent: -80°C for 1 year<br>Actual storage temperature shall be subject to the COA. |



## Biological Description

|                            |   |
|----------------------------|---|
| Description                | AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, causing mitotic delay and arresting cells in prometaphase, followed by increased apoptosis. It targets Aurora-A/-B/-C with K <sub>d</sub> values ranging from 23–289 nM.  |
| Targets(IC <sub>50</sub> ) | Apoptosis,Aurora Kinase,PLK   |
| In vitro                   | AAPK-25 inhibits the growth of HCT-116, Calu6, A549, and MCF-7 cells (IC <sub>50</sub> s: 0.4, 5.3, 11.6, and 2.3 μM). It induces apoptosis in a dose-dependent manner in the HCT-116 cell line, significantly increases histone H3Ser10 phosphorylation, indicating a marked mitotic block, and notably inhibits the mitotic spindle checkpoint. |
| In vivo                    | AAPK-25 enhances the survival rate in the BALB/c nude mice tumor xenograft model.   |

## Solubility Information

|            |  |
|------------|--|
| Solubility | DMSO: 50 mg/mL (113.04 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|--|

## Preparing Stock Solutions

|       | 1mg       | 5mg       | 10mg       |
|-------|-----------|-----------|------------|
| 1 mM  | 2.2608 mL | 11.304 mL | 22.6081 mL |
| 5 mM  | 0.4522 mL | 2.2608 mL | 4.5216 mL  |
| 10 mM | 0.2261 mL | 1.1304 mL | 2.2608 mL  |
| 50 mM | 0.0452 mL | 0.2261 mL | 0.4522 mL  |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Qi B, et al. Discovery of inhibitors of Aurora/PLK targets as anti-cancer agents. J Med Chem. 2019 Aug 5.  
Liang L, Shen Z, Zhang K, et al. DLGAP5 upregulates E2F1 to promote prostate adenocarcinoma neuroendocrine differentiation. Life Sciences. 2025: 123442.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481